Bil­lion­aire-backed Ju­ve­nes­cence spins out an­ti-ag­ing, AI start­up Na­pa Ther­a­peu­tics

The bil­lion­aire-backed start­up Ju­ve­nes­cence — best known for its big plans to tack­le ag­ing — is spin­ning out a new com­pa­ny to de­vel­op re­search out of the Buck In­sti­tute for Re­search on Ag­ing.

The new­ly formed ven­ture, called Na­pa Ther­a­peu­tics, is de­vel­op­ing tech from the labs of Er­ic Verdin, the Buck In­sti­tute’s pres­i­dent and CEO. The work is in nicoti­namide ade­nine din­u­cleotide (NAD+) me­tab­o­lism, with Na­pa hold­ing rights to the tech and IP from the in­sti­tute.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER